Acceptance of intanza® 9 μg intradermal influenza vaccine in routine clinical practice in australia and argentina

Advances in Therapy

Volumn 28, Issue 8, 2011, Pages 640-649

  Eizenberg, Peter ^a   Booy, Robert ^b   Naser, Nadim ^c   Mason, Glen ^c   Stamboulian, Daniel ^d   Weber, Françoise ^e  

^a North East Valley Division of General Practice ^*  (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^c Sanofi Pasteur   (Australia)

^d Fundacion Centro de Estudios Infectologicos   (Argentina)

^e SANOFI PASTEUR   (France)

Author keywords

Acceptability; Influenza; Intradermal; Seasonal; Trivalent inactivated; Vaccine

Indexed keywords

INFLUENZA VACCINE;

ABNORMAL SENSATION; ADULT; AGED; ARGENTINA; ARTICLE; ATTITUDE TO HEALTH; AUSTRALIA; CLINICAL PRACTICE; CONTROLLED STUDY; FEMALE; HEALTH PERSONNEL ATTITUDE; HEALTH SURVEY; HUMAN; INJECTION PAIN; MALE; OFF LABEL DRUG USE; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT PREFERENCE; PATIENT SATISFACTION; SEASONAL INFLUENZA;

ADOLESCENT; ADULT; ARGENTINA; AUSTRALIA; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; INJECTIONS, INTRADERMAL; MIDDLE AGED; VACCINATION; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 82455187935     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-011-0042-0     Document Type: Article

References (14)

1. Tosh PK, Jacobson RM, Poland GA. Influenzavaccines: From surveillance through production toprotection. Mayo Clin Proc. 2010;85:257-273.
2. Barker WH, Mullooly JP. Pneumonia and influenzadeaths during epidemics: Implications forprevention. Arch Intern Med. 1982;142:85-89. (Pubitemid 12207609)
3. Blank PR, Schwenkglenks M, Szucs TD. Vaccinationcoverage rates in eleven European countriesduring two consecutive influenza seasons. J Infect.2009;58:446-458.
4. Prausnitz MR, Mikszta JA, Cormier M., et al.Microneedle-based vaccines. Curr Top MicrobiolImmunol. 2009;333:369-393.
5. Laurent PE, Bonnet S, Alchas P., et al. Evaluationof the clinical performance of a new intradermalvaccine administration technique and associateddelivery system. Vaccine. 2007;25:8833-8842. (Pubitemid 350192056)
6. Atmar RL, Patel SM, Keitel WA. Intanza®: A newintradermal vaccine for seasonal influenza. ExpertRev Vaccines. 2010;9:1399-1409.
7. Arnou R, Icardi G, De Decker M., et al. Intradermalinfluenza vaccine for older adults: A randomizedcontrolled multicenter phase III study. Vaccine.2009;27:7304-7312.
8. European Medicines Agency. Assessment report forIntanza®. In. London: European Medicines Agency;2009.
9. Reygrobellet C, Viala-Danten M, Meunier J., et al.Perception and acceptance of intradermal influenzavaccination: Patient reported outcomes from phase3 clinical trials. Hum Vaccin. 2010;6:336-345.
10. Jabbal-Gill I. Nasal vaccine innovation. J DrugTarget. 2010;18:771-786.
11. Kweon MN. Sublingual mucosa: A new vaccinationroute for systemic and mucosal immunity.Cytokine. 2011;54:1-5.
12. Nicolas JF, Guy B. Intradermal, epidermal andtranscutaneous vaccination: From immunology toclinical practice. Expert Rev Vaccines. 2008;7:1201-1214.
13. Madjid M, Alfred A, Sahai A., et al. Factorscontributing to suboptimal vaccination againstinfluenza: Results of a nationwide telephone surveyof persons with cardiovascular disease. Tex HeartInst J. 2009;36:546-552.
14. Kroneman MW, van Essen GA. Stagnatinginfluenza vaccine coverage rates among high-risk groups in Poland and Sweden in 2003/4 and2004/5. Euro Surveill. 2007;12:E1-2.